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Background: The recommended maximum age and time window for intravenous alteplase treatment of acute ischemic
stroke differs between the Europe Union and United States.
Aims:We compared the effects of alteplase in cohorts defined by the current Europe Union or United States marketing
approval labels, and by hypothetical revisions of the labels that would remove the Europe Union upper age limit or
extend the United States treatment time window to 4.5 h.
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Methods: We assessed outcomes in an individual-patient-data meta-analysis of eight randomized trials of intravenous
alteplase (0.9mg/kg) versus control for acute ischemic stroke. Outcomes included: excellent outcome (modified Rankin
score 0–1) at 3–6 months, the distribution of modified Rankin score, symptomatic intracerebral hemorrhage, and 90-day
mortality.
Results: Alteplase increased the odds of modified Rankin score 0–1 among 2449/6136 (40%) patients who met the
current European Union label and 3491 (57%) patients who met the age-revised label (odds ratio 1.42, 95% CI 1.211.68
and 1.43, 1.231.65, respectively), but not in those outside the age-revised label (1.06, 0.901.26). By 90 days, there was
no increased mortality in the current and age-revised cohorts (hazard ratios 0.98, 95% CI 0.761.25 and 1.01, 0.86–1.19,
respectively) but mortality remained higher outside the age-revised label (1.19, 0.99–1.42). Similarly, alteplase increased
the odds of modified Rankin score 0-1 among 1174/6136 (19%) patients who met the current US approval and 3326
(54%) who met a 4.5-h revised approval (odds ratio 1.55, 1.192.01 and 1.37, 1.171.59, respectively), but not for those
outside the 4.5-h revised approval (1.14, 0.971.34). By 90 days, no increased mortality remained for the current and
4.5-h revised label cohorts (hazard ratios 0.99, 0.771.26 and 1.02, 0.87–1.20, respectively) but mortality remained
higher outside the 4.5-h revised approval (1.17, 0.98–1.41).
Conclusions: An age-revised European Union label or 4.5-h-revised United States label would each increase the
number of patients deriving net benefit from alteplase by 90 days after acute ischemic stroke, without excess mortality.
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Introduction
Despite the availability of reliable information about
the factors determining the benefit–risk relationship
for alteplase in acute ischemic stroke, there are wide
regional differences in the market authorizations for
the drug, which may explain variations in its use
between countries. Two key differences concern the
upper age limit and maximum permitted time to treat-
ment set by regulators. In the European Union (EU),
the upper age limit for safe treatment is set at 80 years
and the time window for treatment is 0–4.5 h from
stroke onset.1 These contrast with the stricter 0–3-h
time window but lack of an explicit upper age limit in
the United States (US).2 In contrast to these regulatory
statements, the scientific guidelines issued by the
respective regional professional bodies (from the
American Stroke Association/American Heart
Association (ASA/AHA) and the European Stroke
Organisation (ESO)) recommend treatment within
4.5 h in both regions. These guidelines do not specify
an age limit in Europe, but in the US they stipulate an
age limit of 80 years if treating between 3 and 4.5 h
(Table 1).3,4 Marketing labels in other parts of the
world also vary in criteria, mostly with respect to age
limit, treatment time window, and in the case of Japan,
in the recommended dose.5 Many clinicians, especially
those in less specialized settings, may adhere to the
more conservative regulatory labels rather than the
more inclusive professional guidelines.6,7 It is therefore
possible that modification of the labeling in the US and
in the EU would enable a larger number of patients to
be treated and achieve improved outcome from acute
ischemic stroke.
We have previously shown that intravenous alteplase
increases the odds of achieving an excellent outcome
(modified Rankin score (mRS) 0–1), and of gaining
an improvement in mRS when used within 4.5 h, with
earlier treatment yielding a larger benefit, and that the
benefit is independent of age.12,13 While achieving this
functional benefit, alteplase also increases the early risk
of fatal intracerebral hemorrhage but, if treatment is
given within 4.5 h, this is completely offset by a later
survival benefit. Hence, by 90 days, there was no excess
risk of mortality.12,14 Indeed, long-term survival data
from the largest trial of alteplase in acute ischemic
stroke, the third international stroke trial, suggest
that further gains in survival might continue to accrue
among early treated patients beyond 90 days.15
Aims
Using the individual data available in the Stroke
Thrombolysis Trialists’ Collaboration (STT), we
sought to determine the likely impact on estimates of
the benefits and potential harm of alteplase if current
US and EU market approvals were modified to recom-
mend treatment up to 4.5 h with no upper age
restriction.
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Methods
Patient-level data from nine randomized trials of alte-
plase in acute ischemic stroke were available,12,16–22 but
one of those trials (ECASS I17) was excluded from the
current analysis because it tested alteplase at 1.1mg/kg
rather than the approved dose of 0.9mg/kg. For the
eight other trials that tested alteplase at a dose of
0.9mg/kg, the search and statistical methods and out-
comes used in the current report are the same as those
used in previous publications,12–14,23 with the exception
that analyses were conducted separately in respect of
the EU and US labels. For each label, we aimed to
examine the effects of alteplase among: (1) those who
would have met existing criteria; (2) those who would
have met hypothetical revisions (i.e. no upper age limit
in the EU or a 4.5-h time window in US), and (3) those
who would have remained outside revised labels.
In brief, for each of these sets of patients, the pro-
portional effects of alteplase on an excellent stroke out-
come (mRS 0–1), on symptomatic intracerebral
hemorrhage (sICH, defined in three ways: type 2 par-
enchymal hemorrhage (PH-2) within seven days; Safe
Implementation of Thrombolysis in Stroke Monitoring
Study’s (SITS-MOST) hemorrhage within 24–36 h and
on fatal intracerebral hemorrhage within seven days)
were estimated by trial-stratified logistic regression.
For subgroup analyses by treatment duration (30 h,
>3 to 45 h, and >45 h), age (80 years and >80
years), and stroke severity (NIHSS 4, 5–10, 11–15,
16–21, and 22), these estimates were further adjusted
for these three baseline features and for the relevant
interaction term(s). The proportional effect of alteplase
on 90-day mortality, overall and within the previously
presented12 risk periods 1–7 days, 8–30 days, and 31–90
days, was estimated using trial-stratified Cox regression
without adjustment for other characteristics, while esti-
mates of the common odds ratio for any improvement
in mRS with alteplase were obtained for each trial using
a proportional odds model adjusted for treatment allo-
cation, with results subsequently meta-analyzed across
trials.24,25 For each set of patients, sensitivity analyses
re-estimated these main effects after additional adjust-
ment for baseline treatment delay, age, and stroke
severity.
In seven of the eight trials, mRS was assessed at
three months, but in the third international stroke
trial (IST-3) the Oxford Handicap Scale, which is simi-
lar to mRS, was assessed at six months. As pre-speci-
fied23 we present functional outcome (mRS) at 3–6
months, but mortality at 90 days.
All estimates of treatment effect are provided with
their 95% CIs with p values that are deemed conven-
tionally significant, without allowance for multiple test-
ing, at the 5% significance level. Analyses were done
using SAS version 9.3 (SAS Institute, Cary) and R ver-
sion 2.11.1 (https://www.R-project.org).
Results
Effects among patients who would have met the
current EU label
A total of 2449/6136 (40%) patients from the eight
trials would have met the current EU label criteria
(Tables 2 and 3). When used according to the
existing EU label, alteplase increased the odds of
achieving mRS 0–1 (OR 1.42, 1.211.68) and of
gaining any improvement in mRS (common OR
1.27, 1.111.47) (Figure 1(a) and online
Supplementary Figure 1(a)).
The odds for sICH were increased by alteplase: OR
5.25 (2.73–10.13) for parenchymal hemorrhage type 2;
OR 5.87 (2.45–14.08) for the SITS-MOST definition;
and OR 8.27 (2.47–27.64) for fatal ICH within seven
days (online Supplementary Figures 2(a), 3(a), and
4(a)). The average absolute excess risk of fatal ICH
within seven days was 1.7% (0.9%–2.5%) (online
Supplementary Figure 4(a)). There was no evidence of
an increase in 90-day mortality with alteplase: hazard
ratio (HR) 0.98 (0.76–1.25; Figure 2).
Effects among patients who would have met an
age-revised EU label
Among 3491/6136 (57%) patients who would have met
an EU label revised to include patients aged >80 (online
Supplementary Tables 1 and 2), the odds ratios for
achieving an excellent functional outcome and for gain-
ing any improvement in mRS were 1.43 (1.231.65) and
1.29 (1.141.45), respectively (Figure 1(b) and online
Supplementary Figure 1(b)). For excellent functional
outcome, benefit was found independently in both the
0–3 h (OR 1.78, 1.33–2.38) and the 3–4.5 h (OR 1.31,
1.07–1.60) cohorts, and in those aged >80 years (OR
1.69, 1.17–2.44) (Figure 1(b)).
The odds of sICH were increased by alteplase: OR
5.23 (3.18–8.62) for parenchymal hemorrhage type 2,
OR 6.87 (3.25–14.52) for the SITS-MOST definition
and OR 8.75 (3.45–22.21) for fatal ICH within seven
days (online Supplementary Figures 2(b), 3(b), and
4(b)). The average absolute excess risk of fatal ICH
within seven days was 2.1% (1.3%–2.8%) (online
Supplementary Figure 4(b)). There was no significant
increase in 90-day mortality in this age-extended group
(HR 1.01, 0.86–1.19; Figure 2). (Note that stratification
by trial and the non-proportional influence of alteplase
on survival generates this HR despite crude 90-day
mortality being 16.1% with alteplase and 16.5% with
control.)
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Effects among patients who would not have met
an age-revised EU label
Overall, among all patients who would not have met an
age-revised EU label (online Supplementary Table 1),
there was no significant effect on excellent outcome
(OR 1.06, 0.901.26) nor for any mRS improvement
(common OR 0.98, 0.85–1.12) (Figure 1(c) and online
Supplementary Figure 1(c)). The odds of sICH were
increased: for PH2 the OR was 7.37 (4.40–12.33), for
SITS-MOST sICH 7.76 (3.69–16.29), and for fatal ICH
within seven days 8.71 (3.44–22.03) (online
Supplementary Figures 2(c), 3(c), and 4(c)). The aver-
age absolute excess risk of fatal ICH within seven days
was 2.8% (1.9%–3.9%) (online Supplementary Figure
4(c)). There was an increase in early mortality (i.e.
deaths within seven days) (HR 1.42, 1.08–1.87) which
was not offset by improved longevity in survivors,
giving an HR for 90-day mortality of 1.19 (0.99–1.42)
(Figure 2).
Effects among patients who would have met the
current US label
A total of just 1174/6136 (19%) patients from the eight
trials would have met the current US label criteria
because of the low number of patients treated within
the 3-h time window (Tables 2 and 3). Among such
participants, alteplase increased the odds of achieving
mRS 0-1 (OR 1.55, 1.19–2.01) and of gaining any
improvement in mRS (common OR 1.33, 1.091.63)
(Figure 3(a) and online Supplementary Figure 5(a)).
The odds of sICH were increased by alteplase: OR
6.38 (2.47–16.47) for PH2, OR 9.55 (2.22–41.06) for the
SITS-MOST definition, and OR 15.19 (2.01–114.9) for
fatal ICH (online Supplementary Figures 6(a), 7(a), and
8(a)). The average absolute excess risk of fatal ICH
within seven days was 2.5% (1.2%–3.8%) (online
Supplementary Figure 8(a)). Despite this increased
early risk, there was no evidence of an increase in 90-
day mortality with alteplase (HR 0.99, 0.77–1.26;
Figure 2).
Effects among patients who would have met a
4.5-h-revised US label
Among 3326/6136 (54%) patients who would have met
a 4.5-h-revised US label criteria, the odds ratios for
achieving an excellent functional outcome and for gain-
ing any improvement in mRS were 1.37 (1.171.59)
and 1.24 (1.101.40), respectively (Figure 3(b) and
online Supplementary Figure 5(b)). For excellent func-
tional outcome, benefit was found independently in
both the 0–3 h (OR 1.68, 1.25–2.25) and the 3–4.5 h
(OR 1.35, 1.09–1.66) cohorts (Figure 1(b)).T
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Figure 1. Effect of rt-PA on an excellent stroke outcome (mRS 0–1) in groups defined by the current European Union label as
well as a European Union label without an upper age restriction. For (a–c), the odds ratios represented by open diamonds or open
squares are derived from trial-stratified logistic regression estimates adjusted only for treatment allocation. By contrast, the odds
ratios represented by filled squares are derived from trial-stratified logistic regression models which allow separate estimation of
the OR at different levels of, respectively, treatment delay, age, and baseline NIHSS, with further adjustment for the other two
baseline characteristics (but not for possible interactions with those characteristics). Consequently, the information-weighted
average of the subgroup-specific estimates does not necessarily equal the summary odds ratios shown by the open diamonds
(main effect estimates which are additionally adjusted for baseline treatment delay, age, and baseline NIHSS are shown in online
Supplementary Table 4).
0.5 1 1.5 2 2.5
rt−PA Control Odds ratio (95% CI)
rt−PA worse rt−PA better
a) Patients who would have met the current EU label
Treatment delay
≤ 3 hours 162/368 (44.0%) 119/377 (31.6%)
>3, ≤ 4.5 hours 373/839 (44.5%) 325/865 (37.6%)
Age
≤ 80 years 535/1207 (44.3%) 444/1242 (35.7%)
Baseline NIHSS
0−4 105/131 (80.2%) 76/112 (67.9%)
5−10 298/500 (59.6%) 253/499 (50.7%)
11−15 89/300 (29.7%) 80/304 (26.3%)
16−21 40/222 (18.0%) 33/245 (13.5%)
≥ 22 3/54 (5.6%) 2/82 (2.4%)
Subtotal 1.42 (1.21 − 1.68)535/1207 (44.3%) 444/1242 (35.7%)
b) Patients who would have met an age−revised EU label
Treatment delay
≤ 3 hours 210/609 (34.5%) 145/594 (24.4%)
>3, ≤ 4.5 hours 425/1121 (37.9%) 367/1167 (31.4%)
Age
≤ 80 years 535/1207 (44.3%) 444/1242 (35.7%)
>80 years 100/523 (19.1%) 68/519 (13.1%)
Baseline NIHSS
0−4 129/172 (75.0%) 92/153 (60.1%)
5−10 347/657 (52.8%) 293/661 (44.3%)
11−15 106/414 (25.6%) 87/410 (21.2%)
16−21 47/368 (12.8%) 38/391 (9.7%)
≥ 22 6/119 (5.0%) 2/146 (1.4%)
Subtotal 1.43 (1.23 − 1.65)635/1730 (36.7%) 512/1761 (29.1%)
c) Patients who would NOT have met an age−revised EU label
Treatment delay
≤ 3 hours 30/129 (23.3%) 22/130 (16.9%)
>3, ≤ 4.5 hours 18/138 (13.0%) 30/148 (20.3%)
>4.5 hours 351/1081 (32.5%) 315/1019 (30.9%)
Age
≤ 80 years 345/994 (34.7%) 323/969 (33.3%)
>80 years 54/354 (15.3%) 44/328 (13.4%)
Baseline NIHSS
0−4 97/156 (62.2%) 83/151 (55.0%)
5−10 204/514 (39.7%) 204/512 (39.8%)
11−15 59/285 (20.7%) 65/270 (24.1%)
16−21 24/216 (11.1%) 10/212 (4.7%)
≥ 22 15/177 (8.5%) 5/152 (3.3%)
Subtotal 1.06 (0.90 − 1.26)399/1348 (29.6%) 367/1297 (28.3%)
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Figure 2. Effect of rt-PA on 90-day mortality in groups defined by the current and extended labels in the EU and US. For both the
EU and US label, and (a–c), Cox proportional hazards regression with stratification by trial and adjustment only for treatment
allocation was used to estimate the hazard ratio and its 95% confidence interval for each period at risk. Patients can only
contribute to a particular risk period if they have already survived any preceding periods. Denominators therefore reflect the
numbers of patients at risk of death at the start of each shown period.
0.3 0.5 1 1.5 2
Hazard ratio (95% CI)rt−PA Control
rt−PA better rt−PA worse
US label
a) Patients who would have met the current label
Days 1 − 7 1.05 (0.70−1.58)49/600 (8.2%) 44/574 (7.7%)
Days 8 − 30 0.96 (0.63−1.44)46/551 (8.3%) 45/530 (8.5%)
Days 31 − 90 0.95 (0.60−1.51)37/505 (7.3%) 35/485 (7.2%)
Total: 90−day mortality 0.99 (0.77 − 1.26)132/600 (22.0%) 124/574 (21.6%)
b) Patients who would have met a 4.5−hour−revised label
Days 1 − 7 1.38 (1.06−1.80)131/1653 (7.9%) 98/1673 (5.9%)
Days 8 − 30 0.91 (0.68−1.22)86/1522 (5.7%) 99/1575 (6.3%)
Days 31 − 90 0.77 (0.57−1.03)75/1436 (5.2%) 102/1476 (6.9%)
Total: 90−day mortality 1.02 (0.87 − 1.20)292/1653 (17.7%) 299/1673 (17.9%)
c) Patients who would NOT have met a 4.5−hour−revised label
Days 1 − 7 1.40 (1.05−1.86)114/1425 (8.0%) 80/1385 (5.8%)
Days 8 − 30 0.96 (0.70−1.32)73/1310 (5.6%) 76/1305 (5.8%)
Days 31 − 90 1.14 (0.78−1.64)60/1237 (4.9%) 53/1229 (4.3%)
Total: 90−day mortality 1.17 (0.98 − 1.41)247/1425 (17.3%) 209/1385 (15.1%)
EU label
a) Patients who would have met the current label
Days 1 − 7 1.37 (0.95−1.98)65/1207 (5.4%) 50/1242 (4.0%)
Days 8 − 30 1.04 (0.65−1.67)35/1142 (3.1%) 35/1192 (2.9%)
Days 31 − 90 0.51 (0.31−0.84)23/1107 (2.1%) 47/1157 (4.1%)
Total: 90−day mortality 0.98 (0.76 − 1.25)123/1207 (10.2%) 132/1242 (10.6%)
b) Patients who would have met an age−revised label
Days 1 − 7 1.39 (1.06−1.82)122/1730 (7.1%) 92/1761 (5.2%)
Days 8 − 30 1.02 (0.76−1.37)87/1607 (5.4%) 90/1669 (5.4%)
Days 31 − 90 0.67 (0.50−0.91)69/1520 (4.5%) 108/1579 (6.8%)
Total: 90−day mortality 1.01 (0.86 − 1.19)278/1730 (16.1%) 290/1761 (16.5%)
c) Patients who would NOT have met an age−revised label
Days 1 − 7 1.42 (1.08−1.87)123/1348 (9.1%) 86/1297 (6.6%)
Days 8 − 30 0.85 (0.62−1.16)72/1225 (5.9%) 85/1211 (7.0%)
Days 31 − 90 1.38 (0.95−2.01)66/1153 (5.7%) 47/1126 (4.2%)
Total: 90−day mortality 1.19 (0.99 − 1.42)261/1348 (19.4%) 218/1297 (16.8%)
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Figure 3. Effect of rt-PA on an excellent stroke outcome (mRS 0–1) in groups defined by the current US label as well as a US
label with a 4.5-h time window. For (a–c), the odds ratios represented by open diamonds or open squares are derived from trial-
stratified logistic regression estimates adjusted only for treatment allocation. By contrast, the odds ratios represented by filled
squares are derived from trial-stratified logistic regression models which allow separate estimation of the OR at different levels of,
respectively, treatment delay, age, and baseline NIHSS, with further adjustment for the other two baseline characteristics (but not
for possible interactions with those characteristics). Consequently, the information-weighted average of the subgroup-specific
estimates does not necessarily equal the summary odds ratios shown by the open diamonds (main effect estimates which are
additionally adjusted for baseline treatment delay, age and baseline NIHSS are shown in online Supplementary Table 4).
0.5 1 1.5 2 2.5
rt−PA Control Odds ratio (95% CI)
rt−PA worse rt−PA better
a) Patients who would have met the current US label
Treatment delay
≤ 3 hours 193/600 (32.2%) 142/574 (24.7%)
Age
≤ 80 years 150/365 (41.1%) 118/377 (31.3%)
>80 years 43/235 (18.3%) 24/197 (12.2%)
Baseline NIHSS
0−4 30/44 (68.2%) 13/25 (52.0%)
5−10 87/169 (51.5%) 79/183 (43.2%)
11−15 40/145 (27.6%) 26/128 (20.3%)
16−21 27/152 (17.8%) 21/143 (14.7%)
≥ 22 9/90 (10.0%) 3/95 (3.2%)
Subtotal 1.55 (1.19 − 2.01)193/600 (32.2%) 142/574 (24.7%)
b) Patients who would have met a 4.5−hour−revised US label
Treatment delay
≤ 3 hours 193/600 (32.2%) 142/574 (24.7%)
>3, ≤ 4.5 hours 387/1053 (36.8%) 333/1099 (30.3%)
Age
≤ 80 years 490/1146 (42.8%) 413/1189 (34.7%)
>80 years 90/507 (17.8%) 62/484 (12.8%)
Baseline NIHSS
0−4 109/149 (73.2%) 85/137 (62.0%)
5−10 307/587 (52.3%) 269/607 (44.3%)
11−15 100/389 (25.7%) 82/373 (22.0%)
16−21 49/349 (14.0%) 36/366 (9.8%)
≥ 22 15/179 (8.4%) 3/190 (1.6%)
Subtotal 1.37 (1.17 − 1.59)580/1653 (35.1%) 475/1673 (28.4%)
c) Patients who would NOT have met a 4.5−hour−revised US label
Treatment delay
≤ 3 hours 47/138 (34.1%) 25/150 (16.7%)
>3, ≤ 4.5 hours 56/206 (27.2%) 64/216 (29.6%)
>4.5 hours 351/1081 (32.5%) 315/1019 (30.9%)
Age
≤ 80 years 390/1055 (37.0%) 354/1022 (34.6%)
>80 years 64/370 (17.3%) 50/363 (13.8%)
Baseline NIHSS
0−4 117/179 (65.4%) 90/167 (53.9%)
5−10 244/584 (41.8%) 228/566 (40.3%)
11−15 65/310 (21.0%) 70/307 (22.8%)
16−21 22/235 (9.4%) 12/237 (5.1%)
≥ 22 6/117 (5.1%) 4/108 (3.7%)
Subtotal 1.14 (0.97 − 1.34)454/1425 (31.9%) 404/1385 (29.2%)
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The odds of sICH were increased by alteplase: OR
5.58 (3.35–9.30) for PH2, OR 7.35 (3.32–16.29) for the
SITS-MOST definition, and OR 9.11 (3.60 – 23.07) for
fatal ICH within seven days (online Supplementary
Figures 6(b), 7(b), and 8(b)). The average absolute
excess risk of fatal ICH within seven days was 2.3%
(1.5%–3.1%) (online Supplementary Figure 8(b)).
There was no significant increase in 90-day mortality
in this cohort (HR 1.02, 0.87–1.20; (Figure 2).
Effects among patients who would not have met a
4.5-h-revised US label
Overall, among patients not satisfying a 4.5-h-revised
US label, there was no evidence of benefit (OR 1.14
(0.971.34) for excellent functional outcome,
common OR 1.03 (0.90–1.18) for any mRS improve-
ment (Figure 3(c) and online Supplementary Figure
5(c)). The odds of sICH were increased: the OR was
6.89 (4.17–11.38) for PH2, 7.19 (3.56–14.50) for the
SITS-MOST definition, and 8.32 (3.28–21.09) for fatal
hemorrhage within seven days (online Supplementary
Figures 6(c), 7(c), and 8(c)). The average absolute
excess risk of fatal ICH within seven days was 2.6%
(1.7%–3.5%) (online Supplementary Figure 8(c)). This
early risk resulted in an increase in early mortality (i.e.
days 1–7) (HR 1.40, 1.05–1.86) that was not offset by
reduced mortality among those who survived the first
week (HR for 90-day mortality 1.17 (0.98–1.41)
(Figure 2).
Effects on the distribution of mRS scores
Figure 4 shows the distribution of the mRS scores at 3–
6 months in each of the three cohorts (on label, on
revised label, and off revised label) within
a. the EU and
b. the US.
These distributions illustrate a similar pattern in the
two regions: in both cases patient cohorts defined by
the hypothetically extended labels derived clear net
benefit, with a shift towards reduced disability and no
significant excess of mortality.
Sensitivity analyses
For each of the contributing cohorts of patients, the
baseline balance in key prognostic variables between
those allocated alteplase and those allocated control is
shown in online Supplementary Tables 3(a) to (f). As
expected, randomization resulted in good balance for
most characteristics in all cohorts. However, among the
1174 patients who would have met the current US label
(online Supplementary Table 3(d)), there was a chance
imbalance in mean age, with those allocated alteplase
on average 1.8 years older than those allocated control.
To assess the impact of this, treatment effect estimates
for each cohort for each of the main outcomes were re-
estimated after additional adjustment for baseline treat-
ment delay, age and stroke severity (online
Supplementary Table 4). For the cohort who would
have met the US label, the adjusted OR estimates
were 1.69 (1.26–2.28) for excellent functional outcome
and 1.42 (1.15–1.76) for any upwards shift in mRS.
Discussion
The regulations that govern medicinal products seek to
ensure that only products that meet standards of qual-
ity and safety, and have reasonable evidence of efficacy,
are marketed. However, there are important differences
between patient eligibility for intravenous alteplase
treatment according to scientific guidelines and to mar-
keting authorizations in both US and EU. The present
analyses from the STT Collaboration indicate that
patients who would have met the criteria of the AHA
or ESO guidelines but would have been excluded by the
regulatory authorization derived significant and clinic-
ally useful benefit by 90 days, with an early increased
risk of death from intracerebral hemorrhage completely
offset by a later improvement in stroke survival. Within
the STT dataset, only two-fifths of patients (mean treat-
ment delay 3.4 h) would have met the current criteria of
the EU label, but this rose to over half (57%; mean
delay 3.3 h) when the age criterion was removed (in
accordance with ESO guidelines). For this extended
group, alteplase yielded an excellent functional out-
come with an OR of 1.43 (1.231.65), without any
excess risk of 90-day mortality (16.1% with alteplase
and 16.5% with control: HR 1.01, 0.86–1.19).
The current US label suggests a shorter time window
for treatment than the EU label, and only 19% (mean
delay 2.3 h) of the individuals in our dataset would have
been included by it. A 4.5-h-revised version of the US
label, however, would have been met by 54% of indi-
viduals (mean delay 3.3 h), and among these patients
the effects of alteplase closely matched those of the
age-revised EU label, with an odds ratio for achieving
excellent outcome of 1.37 (1.171.59), again without
any excess risk of 90-day mortality (17.7% with alte-
plase and 17.9% with control: HR 1.02, 0.871.20).
Among all patients treated with 0.9mg/kg alteplase
who would not have met revised labels in the EU and
the US there was no significant functional benefit yet
they suffered an overall hazard amounting to 2.2–2.6%
excess mortality at day 90, due entirely to the excess in
early fatal ICH. This is consistent with their long
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Figure 4. Distribution of mRS at 36 months by randomized treatment allocation in groups defined by the current and extended
labels in the EU and US. mRS score was ascertained at six months for IST-3 and three months for other trials.
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average treatment delay (4.8 h in both cases) together
with the previously documented observation that the
proportional benefits of intravenous alteplase (but not
the risks) diminish with increased delay. These data
indicate that patients failing to meet scientific guidelines
for intravenous alteplase are not likely to benefit from
alteplase after acute ischemic stroke.
The initial risk of intracerebral bleeding after intra-
venous alteplase is well recognized.14 Despite this, there
was, on average, an improvement in mRS among
patients meeting the current or revised labels. Around
half of the patients who suffered sICH survived beyond
seven days. Even so, the distribution of functional out-
comes by 90 days favors alteplase, implying that func-
tional outcome, survival or both improved sufficiently
in the remaining patients to offset this effect on the
average outcome for the cohort (Figure 4). By 90
days, the excess risk of early death was offset by
increased survival in the treated group. Although we
should not disregard this early risk, it has been appar-
ent from previous analyses that the absolute risk of
serious intracerebral bleeding is higher among patients
who present with severe, and thus likely disabling,
stroke. The survival benefit persists among the treated
group with longer periods of follow-up.12,15 Among
patients who met either revised label, the revisions
had limited impact on the risk of fatal intracerebral
bleeding, since we found the relative and absolute
risks were similar between the current and revised
label cohorts and were well within the margin of
error: absolute excess 2.1% (1.3%–2.8%) for the
revised EU label (currently 1.7% (0.8%–2.5%)) and
2.3% (1.5%–3.1%) for the revised US label (currently
2.5% (1.2%–3.8%)).
Our analyses have limitations: the main one is that
our quantitative estimates of treatment effect might not
be replicable in an equivalent group of patients because
the data from these trials to some extent have defined
the labels and recommendations. Notwithstanding this
caveat, the main observation that estimates of treat-
ment effect were similar for patients eligible for current
and extended labels remains valid. The validity of our
analyses is enhanced by having access to all the relevant
individual patient data, common definitions for most
data items, and stratification of the analyses to retain
any influence of individual trials on the outcome.
Alignment of the US and EU labels on age and time
window may not increase uptake of thrombolysis in
routine practice by the proportions suggested from
our dataset. The case mix of patients enrolled to the
thrombolysis trials represents a combination of various
eligibility criteria applied to a population case mix
which itself will have changed over the 20 years since
some of these trials were conducted. Based on a snap-
shot survey of 10,633 recent thrombolysis treatment
registrations in the United Kingdom (UK) undertaken
by one author (KRL, unpublished data), we estimate
that 42% more patients would meet a 4.5-h-revised US
label than the current US label, and 36% more patients
would meet an age-revised EU label than the current
EU label. These are likely to be conservative estimates,
since some stroke physicians in UK may presently
restrict their use of thrombolysis to the current EU
label criteria. A recent analysis of 56,689 patients’
data from 597 sites registered to the SITS international
registry over 6.5 years reported that if all patients were
treated by using ESO guidelines, an additional 17,031
would receive alteplase, which translates into 1922
more patients with favorable three-month outcomes.26
Summary
Hypothetical revisions of the treatment labels for alte-
plase after acute ischemic stroke, increasing the time
window to 4.5 h for the US criteria and removing the
upper age limit from the EU criteria, substantially
increased the proportion of patients for whom treat-
ment was of net benefit without elevating 90-day mor-
tality. These revisions are in reasonable alignment with
existing ESO recommendations on alteplase use. The
available evidence indicates that the current US and
EU marketing authorizations for the use of intravenous
alteplase following acute ischemic stroke are unduly
restrictive and may well be contributing to unnecessary
disability.
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